Biallelic inherited mutations in the oxidative DNA damage repair gene MUTYH predispose to colorectal adenomas and colorectal carcinoma (CRC) with high penetrance. We investigated whether rare inherited variants in other oxidative DNA damage repair genes predisposed to CRC. Single marker association analyses were assessed under an allelic model with Bonferroni correction for multiple testing. All statistical tests were two-sided. A rare inherited nonsynonymous variant in OGG1 (Gly308Glu), the functional partner of MUTYH, was over-represented in case patients with advanced CRC compared with population-based control subjects (n = 36 of 2142 case patients vs n = 15 of 2175 control subjects in the training phase, P = 1.8 × 10 −3 ; and n = 22 of 1005 case patients vs n = 8 of 1389 control subjects in the validation phase, P = 4.8 × 10 −4 ; P = 1.4 × 10 −5 combined; odds ratio = 2.92, 95% confidence interval = 1.80 to 4.74). Glycine at residue 308 was highly conserved through evolution, and the glutamic acid substitution was predicted as likely to interfere with function. Biallelic inherited and somatic OGG1 mutations were rarely observed in OGG1 Gly308Glu carriers, nor did we find any associated somatic mutator phenotype. These data suggest that OGG1
Inherited factors account for approximately one-third of all colorectal cancers (CRCs) (1) . Up to 6% of case patients carry rare, high-penetrance mutations (2) such as those found in MUTYH, which cause MUTYHassociated polyposis (MAP, OMIM 608456) (3, 4) . Some of the remaining variation in risk is explained by more common, lowpenetrance variants, and genome-wide association studies (GWASs) have identified 20 such alleles (5) (6) (7) .
MUTYH is a base excision repair (BER) DNA glycosylase that removes adenines misincorporated opposite 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxoG), a highly stable product of oxidative DNA damage (8) . BER is particularly important in the colon, where high levels of reactive oxygen species are generated by commensal bacteria and dietary carcinogens (9,10).
Other BER enzymes also protect against oxidative DNA damage; OGG1 and NTH1 remove the damaged base from 8-oxoG:C (11) and 8-oxoG:G base-pairs (12) , respectively, and NEIL1-3 have similar substrate specificities (13) . Further genes involved in this repair process include: MTH1 (14) , APE1 (15) , FEN1 (16) , CSA (17) , CSB (18) , XPC (19) , MSH2 (20) , MSH6 (20) , BRCA1 (21) , BRCA2 (21) , RECQ1 (22) , DNA polymerases β/λ (23, 24) , SMUG1 (25) , JWA (26) , TIGAR (27) , XRCC1 (28) , and PARP-1 (28) .
Here, we investigated whether rare inherited variants in these other oxidative DNA damage repair genes predisposed to CRC. For our training phase (Table 1) , we used germline DNA samples from 2186 unrelated British patients with advanced CRC (aCRC) from UK-national, multicenter, randomized controlled trials [COIN: n = 2073 (29); COIN-B: n=113] and 2176 geographically-matched unrelated British white control subjects (from the UK Blood Services collection) (30, 31) . All patients and control subjects gave informed consent for bowel cancer research (REC 04/MRE06/60, 05/ Q0106/74). Single marker association analyses were assessed under an allelic model (with 1 degree of freedom) using PLINK version 1.07 (http://pngu.mgh.harvard. edu/~purcell/plink/), with correction for multiple testing by Bonferroni. When cell counts were less than five, Fisher exact test was used. All statistical tests were two-sided.
Our training phase cohort has already been used to identify and validate novel CRC-susceptibility loci (6, 7) . To further demonstrate its utility to identify such alleles, we assayed a single genome-wide significant single nucleotide polymorphism (SNP) from each of the 10 other known CRC risk loci (5) . We validated five of these (rs4939827 at 18q21: odds ratio Table 1 , available online).
We therefore used this cohort to investigate whether rare (minor allele frequencies ≤ 1%) inherited nonsynonymous, splicing, or truncating variants in oxidative DNA damage repair genes predisposed to CRC. We catalogued 87 variants (from 17 genes) using dbSNP and our previous studies (32) , of which 47 failed locus conversion. We assayed the 40 remaining variants using Illumina's GoldenGate assay; 12 failed and 10 were monomorphic.
Of the remaining 18 variants, three were over-represented in case patients with aCRC ( * Our training phase cohort consisted of 2186 unrelated British patients with advanced colorectal cancer (aCRC) (1440 were male; mean age at diagnosis = 61.5 years; range = 18-84 years) and 2176 geographically matched unrelated healthy British white control subjects (1101 were male; mean age at sampling = 43.7 years; range = 17-69 years). Based on these sample sizes, we had 76% and 90% power to detect a variant with a minor allele frequency (MAF) of 1% (in case patients) with an odds ratio (OR) of 2.0 and 2.5, respectively, and 63% power to detect a variant with a MAF of 0.5% with an OR of 2.5 (significance level P < .05). We also had 60% power to detect a variant with a MAF of 1% with an OR of 2.5 at P < .0028 (significance level after correction for multiple testing). We focused on oxidative DNA damage repair genes that
were not associated with a human disease. Single marker association analyses were performed using PLINK version 1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/), and aCRC case patients identified as being of nonwhite origin (n = 40) were excluded from the analyses. CI = confidence interval; NA = not applicable. † P values using a χ 2 test or Fisher exact test (n < 5) (all tests were 2-sided). Only ; n = 18 tests) and was assayed in the validation phase. Neither c.434+2T>C in NEIL1 nor Arg7Leu in XRCC1 were statistically significant after correction for multiple testing and were excluded from the validation phase. Genotype concordance rates for duplicate samples (n = 55) in the GoldenGate assay were 100% (990 of 990 genotypes were concordant), GenTrain scores for the 18 single nucleotide polymorphisms analyzed ranged from 0.74 to 0.96, and the overall genotyping success rate was 99.8% (78396 or 78516 genotypes were called successfully). ‡ It has recently been suggested that Arg46Gln in OGG1 may act as a CRC susceptibility allele (33, 34) ; however, we found that similar numbers of aCRC case patients and control subjects carried this variant in a heterozygous state.
Supplementary Figure 1 , available online). Arg7Leu in XRCC1 was in 24 patients and 9 control subjects in a heterozygous state (χ 2 = 7.01; P = 8.1 × 10
). c.434+2T>C in NEIL1 was in 61 patients in a heterozygous state and two patients in a homozygous state as compared with 42 control subjects in a heterozygous state (χ 2 = 5.36; P = 2.1 × 10 −2 ). Only OGG1 Gly308Glu remained statistically significant after correction for multiple testing (P = 3.2 × 10 −2 ). We assayed OGG1 Gly308Glu in our independent validation phase cohort. This consisted of 1053 unrelated case patients with aCRC from further UK-national, multicentre, randomized controlled trials; ninety-five were from COIN/COIN-B (not used in the training phase), together with patients from FOCUS2 (n = 361), FOCUS3 (n = 221) and PICCOLO (n = 376). The control subjects consisted of 1389 samples from the UK Blood Services collection (n = 910, not used in the training phase) and the European Collection of Cell Cultures (n = 479). We confirmed an over-representation of OGG1 ). Combined with our training phase, we found strong evidence for an effect of OGG1 Gly308Glu in contributing to aCRC (OR = 2.92, 95% CI = 1.80 to 4.74; P = 1.4 × 10 −5 ) ( Table 2 ). Glycine at residue 308 in OGG1 was highly conserved through evolution (Supplementary Figure 2, available online) , and in silico analyses predicted the glutamic acid substitution as likely to interfere with function. However, OGG1
Gly308Glu had no effect in an 8-oxoG:C-cleavage assay (37), consistent with the crystal structure (38) and our molecular modeling. OGG1 binds to PARP-1 (39), and RAD52 (40) and affects their activities; therefore, OGG1 Gly308Glu may interfere with these alternative functions.
We determined whether OGG1 variants act in a high-penetrance, autosomal recessive manner and sequenced the OGG1 open reading frame (ORF) in case patients and control subjects that carried OGG1
Gly308Glu
. We found the polymorphism Ser326Cys (rs1052133) in similar numbers of case patients (n = 9 of 50) and control subjects (n = 6 of 23) in a heterozygous state (P = .43). Apart from one case patient homozygous for OGG1
, we identified a Gly308Glu/Ala288Val compound heterozygote and another with Gly308Glu and Ala153Thr. However, we did not find likely pathogenic alleles in 47 other case patients with OGG1
. We also sought but failed to find somatic OGG1 mutations in the primary CRCs (n = 31) from OGG1 Gly308Glu carriers after sequencing the ORF. We noted retention of the wild-type OGG1 allele in 29 (93.5%) of these tumors, with one tumor each showing loss of the wild-type and mutant allele. Therefore, OGG1 is unlikely to function as a high-penetrance, dominant, tumor suppressor gene.
Tumors from patients with MAP have a G:C→T:A mutator phenotype, due to a failure to repair oxidative DNA damage (41) . We sought somatic mutations in the adenomatous polyposis coli (APC) mutation cluster region in CRCs from OGG1 Gly308Glu carriers (n = 22). We found eight somatic Table 3 , available online).
Whereas biallelic inherited mutations in MUTYH predispose to colorectal adenomas and CRC with high penetrance and the associated tumors have a characteristic somatic mutation signature, neither of these observations appear to be true for OGG1
. We therefore suggest that OGG1 Gly308Glu may function as a low-penetrance allele. ), although the reduction in statistical significance may indicate that the association was confounded by age, and we acknowledge that our control cohort was not age-matched to the case patients. All statistical tests were two-sided. For the validation phase, correction for age and sex was not possible because this data was only available for a small number of case patients. We sequenced the OGG1 open reading frame in all case patients and control subjects that carried OGG1
. All OGG1 Gly308Glu genotypes were concordant with the sequencing results. Apart from the one OGG1 Gly308Glu homozygote, we found one Gly308Glu/Ala288Val compound heterozygote [note that Ala288Val impairs glycosylase activity (35, 36) ] and another case patient that carried Gly308Glu and Ala153Thr (not proven to be on opposite alleles). However, we did not find likely pathogenic alleles in the remaining 47 aCRC case patients with OGG1 Gly308Glu for whom we had sufficient germline DNA available. Apart from a single control subject that carried Arg134Gln, none of the remaining 22 control subjects carried additional, potentially pathogenic variants. MAF = minor allele frequency.
